Physician profile
Michelle Hammond
NPI 1528671351
$3,697.43
in general payments reported to CMS, 2019-2025
20 companies · $625 in 2025
The $625 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $903 · 2023: $788 · 2024: $831 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211 · Honoraria: $32.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.52 |
| Honoraria | $32.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,140.05 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $659.77 | 2021-2025 | Hydrus Microstent, Tryptyr, Total30 |
| Johnson & Johnson Vision Care, INC. | $285.46 | 2021-2023 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $252.81 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $231.79 | 2022-2023 | |
| Allergan, INC. | $209.44 | 2022 | |
| Abbvie INC. | $162.48 | 2022-2024 | |
| Kala Pharmaceuticals, INC. | $157.86 | 2021-2022 | |
| Coopervision INC. | $110.88 | 2022-2023 | Myday Contact Lens |
| Harrow Eye, LLC | $106.65 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $71.54 | 2021 | |
| Oyster Point Pharma, INC. | $65.37 | 2022-2024 | Ryzumvi, Tyrvaya |
| Glaukos Corporation | $55.55 | 2021 | |
| Rxsight INC | $45.95 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Rayner Intraocular Lenses Limited | $41.51 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $24.94 | 2025 | |
| Dompe US, INC. | $23.93 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.03 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.67 | 2021 | |
| Amgen INC. | $15.75 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.